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Effects of a Chronic Low Carbohydrate High Fat Diet on Markers of Cholesterol and
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Brent C. Creighton, P.hD.
University of Connecticut, 2015

The long-term safety of low carbohydrate high fat diets (LCHFD) continues to remain
in question. Previous research has shown marked variability in the cholesterol
response among those who adopt a LCHFD, raising concern, as elevated cholesterol
is associated with increased risk for cardiovascular disease. More in-depth analyses
are necessary to determine if elevated cholesterol associated with chronic
consumption of a LCHFD increases atherogenic risk. Assessment of lipoprotein
subfractions and noncholesterol sterol biomarkers provide a greater ability to quantify
atherogenic risk. Twenty highly trained male ultra marathoners habitually consumed
either a traditional high-carbohydrate HC: n=10, %carbohydrate:protein:fat =
57:15:27) diet or a low-carbohydrate (LC; n=10, 10:19:70) diet for an average of 20
mo (range 9 to 36 mo). Serum total (TC), low-density lipoprotein (LDL-C), and highdensity lipoprotein (HDL-C) cholesterol were all greater in the LCHF group (TC: 277.7
± 50.6 vs 168.7 ± 24.4 mg/dL; P=0.0000, LDL-C: 161.3 ± 37.4 vs 88.1 ± 13.7 mg/dL;
P=0.0000, HDL-C: 102.3 ± 26.2 vs 63.9 ± 18.0 mg/dL; P=0.0007). Noncholesterol
sterol biomarkers were used to calculate fractional cholesterol balance and was not
significantly different between groups (0.60 ± 0.16 vs 0.66 ± 0.22). Men in the LCHF
group presented less atherogenic lipoprotein profiles. Mean VLDL particle size was
significantly reduced in the LC group (38.2 ± 4.1 vs 43.65 ± 1.7 nm; P=0.0022), while
mean LDL (21.5 ± 0.34 vs 20.1 ± 0.35 nm; P=0.0102) and HDL (10.2 ± 0.47 vs 9.5 ±

0.47 nm; P=0.0053) particle size were greater. Total LDL particle count was
significantly greater in the LCHF group (1363 ± 343 vs 893 ± 196 nmol/L; P=0.0021).
Although not statistically different (P=0.0021), the LCHF group had 126% less small
LDL particles (160.6 ± 134.8 vs 363.0 ± 245.2 nmol/L; P=0.1013). Total HDL particles
were not significantly different between groups (P=0.1369). HDL particle distribution
was comprised of significantly more atheroprotective large particles (14.8 ± 4.4 vs 8.1
± 3.4 nmol/L; P=0.0013). These results provide further evidence that compared to
HCD, habitual LCHFDs, irrespective of high circulating cholesterol, due not
significantly alter fractional cholesterol balance and shift the lipoprotein profile
towards a more atheroprotective state.
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Chapter 1

Review of Literature
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Current Perspective
Low carbohydrate high fat diets (LCHFD) continue to be a therapeutic means
for improving metabolic and atherogenic risk factors and although no official definition
of LCHF diets exist, arbitrary levels have been defined as less than 50 grams of
carbohydrates per day or less than 10% of total energy intake 1. Many professional
organizations2,3 continue to discourage LCHFD as long-term health outcomes remain
in question. Though few, recent long-term studies, greater than six months in
duration, have shown remarkably promising results for up to twelve months following
a LCHFD4-7. These longitudinal studies, however, measured only mass cholesterol
levels and were conducted with overweight, diabetic subjects where weight loss was
a contributing factor. What remains to be seen, are the implications a LCHFD may
have on cholesterol levels and cardiovascular risk when maintained for chronic
periods of time (6 < months) in healthy normolipidemic individuals.
Published studies investigating the effects of LCHF diets on metabolic health
in healthy, normolipidemic individuals, have shown variable responses in circulating
cholesterol levels [total (TC) and low-density lipoprotein cholesterol (LDL-C)] not
attributable to weight loss8-13. Numerous cross sectional and prospective
investigations have illustrated that LCHF diets improve cardiometabolic risk factors14.
Many if not all of these studies report data on subjects who followed a LCHF diet for
no greater than 4-12 weeks. To our knowledge, no study to date has assessed
measures of cardiovascular disease (CVD) risk and cholesterol balance in healthy,
fit, normolipdemic men, who have followed a LCHFD for longer than six months.
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Cholesterol
The importance of cholesterol in the human body is unquestionable as
disorders in synthesis result in a myriad of adverse syndromes15. Still, elevated levels
of total serum cholesterol and LDL-C are associated with increased risk of
cardiovascular diseases (CVD) such as atherosclerosis, myocardial infraction, and
stroke16,17. Current international guidelines16,17 continue to weigh heavily on
cholesterol markers for the evaluation of CVD risk. It is reasonable to suggest that
total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density
lipoprotein cholesterol (HDL-C) metrics are well known by the lay public, but not well
understood. Published guidelines and practitioners advise patients to keep TC below
200mg/dL, LDL-C under 130mg/dL, and HDL-C over 40mg/dL16 depending on ones
potential risk for CVD. Arguably, the question needing to be asked is whether or not
these values and subsequent guidelines pertaining to serum cholesterol really help
predict CVD risk. Although still a minority, a growing body of researchers and
practitioners are beginning to argue that measuring circulating cholesterol levels have
no relevance for accurately predicting CVD.
Circulating cholesterol levels are themselves highly variable as are indirect
surrogate markers, particularly in response to dietary changes in cholesterol18 such
as can occur on a LCHFD. Cholesterol levels following increased dietary
consumption may decrease, increase, or stay the same. Of particular concern are
variations or increases in LDL-C following cholesterol feeding, which have similarly
been shown under metabolic ward conditions by Sehayek et al 199819.
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It is well established that endogenous cholesterol metabolism is inversely
regulated. Reduced intestinal absorption of cholesterol causes an up-regulation of
cholesterol synthesis, where as increased intestinal absorption causes the liver to
suppress cholesterol synthesis20. Various human studies have suggested that an
individuals ability to down-regulate endogenous cholesterol synthesis in response to
increased cholesterol intake helps limit their plasma lipoprotein responsiveness21,22.
Animal data helps provide further evidence. Species that tolerate and adapt more
efficiently to an increased dietary cholesterol load include those, which have an
innately greater rate of hepatic cholesterol synthesis (rats, mice, squirrel monkeys) 23.
These species down regulate synthesis more readily and are less responsive to
dietary changes of cholesterol. Importantly, these species, which are frequently used
in experiments for studying metabolism, may not translate into suitable models for
human comparison. Humans have lower rates of hepatic cholesterol synthesis and
so are more responsive to dietary changes in cholesterol. Endogenous cholesterol
consumed in the diet mixes with biliary cholesterol in the intestines. Overall, most
cholesterol within the intestinal lumen is actually derived from endogenous sources
(bile), with dietary cholesterol contributing very little. Although highly variable, the
average American consumes approximately 0.4g of cholesterol per day24. Ultimately,
the amount of cholesterol absorbed equals the amount lost (i.e., the body
synthesizes an amount approximately equal to the amount it absorbs 24.

4

Surrogate Markers of Cholesterol Synthesis and Absorption
Serum cholesterol concentrations are derived from two sources; endogenous
cholesterol from hepatic and extra-hepatic synthesis, and exogenous cholesterol
derived from intestinal absorption of dietary and biliary cholesterol23. Absolute
quantification of cholesterol synthesis is difficult and time consuming, requiring
measures of cholesterol output (fecal measurements and bile acids) and dietary
intake to quantify total sterol balance [Output – Intake = Synthesis]. In response to
these methodological difficulties, more recent, less arduous approaches to quantify
cholesterol balance have been developed. These measurements vary but can
include assessment of serum non-cholesterol sterols, synthesis markers (lathosterol
and desmosterol), and absorption markers (beta-sitosterol, campesterol, and
cholestanol). These sterol-based biomarkers are currently used primarily to assess
the cause of hypercholesterolemia and can help to determine therapy selection. In
addition, noncholesterol sterols can be extremely useful in determining and better
understanding disease states25.
The cholesterol balance score is calculated by taking the ratio of cholesterol
synthesis or production measurements and dividing it by cholesterol absorption
measurements. Pre-cholesterol sterols leak into lipoproteins at a rate proportional to
that of their formation in the cholesterol synthetic pathway, thus is the rational for
using them as indicators of synthesis26. In addition, all sterols including plant sterols
are transported in lipoproteins, predominantly the LDL and HDL subfractions 27.
Plasma non-cholesterol sterols are frequently reported as a ratio to cholesterol in
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order to normalize the differences caused by variable levels of lipoproteins that
transport cholesterol and the sterols28.

Cholesterol Synthesis Pathway
The process of cholesterol synthesis is complex, highly regulated, and
controlled by a myriad of factors. Zoosterol’s or cholesterol that is synthesized in
mammalian cells originates from acetate. Figure 1 illustrates an overly simplified
version of the important steps in the cholesterol synthesis pathway29.

Figure 1: Cholesterol synthesis pathways

As shown above, acetate is converted to 3-hydroxy-3-methyl-glutaryl-CoA (HMGCoA) by HMG-CoA synthase and then to mevalonate by HMG-CoA reductase. This
conversion step, HMG-CoA reductase, is where statin drugs are utilized to stop
cholesterol synthesis. Mevalonate is converted to squalene and finally to lanosterol.
The final stages of cholesterol synthesis shuttle lanosterol through two distinct
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synthetic pathways, the Kandutsch-Rusell30 pathway and the Bloch pathway.
Accounting for nearly 80% of endogenous cholesterol synthesis, the KandutschRusell pathway converts lanosterol first to lathosterol, then to 7-dehydrochoolesterol,
and finally cholesterol. Conversely, the Bloch pathway accounts for the remaining
20%, converting desmosterol to cholesterol. Although yet to be fully mapped out, it is
thought that both pathways are likely independently regulated and share many of the
same enzyme pathways15. Intermediary sterols, squalene, lathosterol, desmosterol
can and are used as biomarkers to evaluate cholesterol synthesis31,32. Elevated
concentrations of these markers indicate increased endogenous production. The
value of measuring cholesterol precursors lies with the assumption that serum they
leak into plasma lipoproteins at a rate relative to that of their formation in the
synthetic pathway26.
Lathosterol and desmosterol are two of the major cholesterol precursors which
can be used as markers of hepatic synthesis33,34. Both precholesterol sterols
maintain very low circulating levels while transported and distributed in a very similar
manner to that of cholesterol. Inherited metabolic diseases or abnormal clinical
conditions (fatty liver disease or insulin résistance) may cause an elevation in either
of these sterols35. In particular, cholesterol precursors show a high degree of
association with fecal cholesterol synthesis, making them a strong alternative option.
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Mechanism of Cholesterol Absorption
The manner by which cholesterol is absorbed from the gut lumen is a tightly
regulated process which has been studied extensively36,37. Intestinal cholesterol
originates from dietary absorption, the hepatobilary system, and intestinal epithelial
slothing, contributing roughly 2000mg/day37. The standard western diet on average
contributes about 300-500 mg of thus total through intestinal absorption. Absorbed
cholesterol is transported in micelles, which form in conjunction with other newly
absorbed lipids (phospholipids and monoglycerides) and the help of bile salts.
Micelles then facilitate transport of cholesterol to the brush border of the small
intestines where cholesterol is removed and unesterified cholesterol passes through
to the enterocytes by way of the Niemann-Pick C1-like (NPC1) transporter. Once
absorbed, cholesterol is then esterified by acyl-CoA cholesterol acyltrasnferase
(ACAT). Efflux from the enterocytes is mediated by intestinal ATP-binding cassette
transporters (ABC) G5 and G8 proteins, which are highly sensitive to plant sterols.
Genetic variances in this protein can result in hyperabsorption of cholesterol38 and
considering an estimated 5% of plant sterols are absorbed from the gut 39, elevated
levels can be considered toxic.
Once absorbed and esterified, cholesterol is then packaged and transported to
the liver in chylomicrons, where newly absorbed cholesterol has a direct impact on
lipoprotein production and removal pathways 23,40. Between individuals, differences in
enzyme kinetics (Km and/or Vmax) related to cholesterol absorption is a likely factor
influencing cholesterol flux as is Apo E genotype41; this has not been found true in all
cases19. Overall, the precise mechanism regulating cholesterol homeostasis has yet
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to be fully mapped out. Still, effects of circadian rhythm, body weight, and diet on
cholesterol response clearly demonstrate the presence of genetically determined
differences that control a person’s cholesterol responsiveness19,42.
The assessment of hypercholesterolemia can be conducted using plant sterol
biomarkers β-sitosterol and campesterol, the major phytosterols present in human
serum ad tissues. Phytosterols serve a supporting role in plant membrane function,
not unlike cholesterol in animals but serve no function in human physiology. Naturally
more hydrophobic than animal sterols, plant sterols consumed in the diet
endogenously inhibit cholesterol absorption by competing for incorporation into
micelles and transport through the NPC1 transporter43. Ratios of serum phytosterols
to cholesterol largely depend on absorption efficiency, biliary secretion, and the
amount consumed in the diet. Quantification of β-sitosterol and campesterol, when
normalized to cholesterol, act as surrogates for evaluating cholesterol absorption
because humans do not produce phytosterols44.
Although less commonly used, cholestanol can also be used to assess
absorption rates. Cholestanol is a synthesized metabolite of cholesterol which exists
ubiquitously throughout the body at a concentration of roughly 1/500 to 1/800 of
cholesterol45. Similar to other noncholesterol sterols, accumulation of cholestanol
results in adverse pathological conditions. Similar to plant sterol absorption, elevated
levels of cholestanol in the circulation is indicative of increased absorption at the gut.
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Considerations for Lipid Assessment
In low carbohydrate studies, weight loss is frequently both a desired outcome
as well as a useful tool for subject recruitment. Still, caution is advised when
interpreting changes in lipids (cholesterol and triglycerides). A meta-analysis
conducted by Dattilo and Kris-Etherton46 concluded that for every kilogram of body
weight lost, there is an associated 0.015 mmol/L reduction in serum triacylglycerols.
Furthermore, whether subjects are actively losing weight or weight stable has been
shown to have an effect on both the magnitude and direction of cholesterol levels 47
making weight loss, independent of diet, a potential confounding factor when
evaluating lipid levels in dietary studies. In addition, weight loss itself likely plays a
large role in influencing the lipoprotein profile. Wood et al.14 illustrated that a LCHFD
in conjunction with weight loss helped improve lipoprotein subclasses. Similarly,
Katzel et al.48 showed weight loss to aid in the favorable redistribution of lipoprotein
subclasses. Thus, it is impetrative to consider weight loss when assessing changes
in lipids.
An additional consideration when evaluating changes in lipids is whether or
not obese and normal weight individuals respond differently to dietary cholesterol.
The mechanism of dietary cholesterol has been well established49,50. Increased
consumption of dietary cholesterol contributes to the already recycled biliary
cholesterol pool and increases the volume of cholesterol entering the liver. Upon
exposure to increased cholesterol levels, the liver down regulates expression of LDL
receptors on hepatocytes. Subsequently, clearance of LDL from the plasma
decreases and circulating cholesterol increases until a new steady has been

10

established. This mechanism offers an explanation as to why obese individuals or
individuals with naturally elevated cholesterol, may be less responsive to changes in
dietary cholesterol. That is, people with elevated cholesterol, such as obese persons,
tend to have higher rates of total body cholesterol synthesis and a larger pool of
cholesterol circulating from the gut back to the liver51. Thus, a person with elevated
cholesterol would have a lower response to dietary cholesterol because the amount
taken in the with the diet would be small compared with the large amount already
present in the enterohepatic cholesterol pool and it would, therefore, not contribute to
further suppression of the LDL receptor20. In addition, there may be a link between
obesity, insulin resistance, and diminished cholesterol absorption, however this has
yet to be seen. Apart from genetic influence, the opposite can likely be said about
non-obese, normolipidemic individuals, that dietary cholesterol is likely to more
greatly effect cholesterol levels due to a lower circulating cholesterol pool.

Lipoproteins
Lipoproteins are particles that function to carry and transport TGs and
cholesterol throughout the body. Essential to cell structure and metabolism, both TGs
and cholesterol are hydrophobic molecules, which cannot move freely within the
fluidic cardiovascular system. Thus, the body has engineered an eloquent system to
transport these molecules. Lipoproteins are comprised of apolipoproteins, which
function as ligands and in structural integrity of the molecule, a phospholipid bilayer
(hydrophilic on the outside and hydrophobic on the inside), TGs, and cholesterol. The
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major apolipoproteins present and the relative contents of all the lipid components
vary among different classes of lipoproteins.
Following the ingestion of a meal, the intestines packages consumed lipids
into chylomicrons for transport around the body. Chylomicrons are primarily TG filled
lipoproteins, which make their way towards the liver depositing fatty acids along the
way in adipose, cardiac, and skeletal muscle tissues52,53. The liver produces VLDLs
which function as the primary transport vehicle of TGs and free fatty acid delivery52.
Removal of TGs from the VLDL core produces metabolic by-products known as
LDLs. In most normal physiological conditions, these are the primary carries of
circulating plasma cholesterol. All three of these lipoproteins, chylomicrons, VLDLs,
and LDLs, carry apoB, in addition to other apolipoproteins. HDLs carry other
apolipoproteins known as apoAI and apoAII. Nascent HDL particles are produced by
the both liver and intestines. These newly formed HDL particles mature as they
become enriched with additional other apolipoproteins and lipids through an
exchange with chylomicrons and VLDLs52,53. Size and density of the various
lipoproteins vary with chylomicrons being the largest and least dense, to the smallest
and most dense HDL. Each lipoprotein class can further be broken down into a
spectrum of distinct particles that vary in size, density, relative proportions of lipid and
protein, as well as atherogenicity52. Figure 3 below illustrates the varying degree of
subclasses, which have been discovered for each distinct lipoprotein class.
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Low-density lipoproteins (LDL) are the chief cholesterol-carrying lipoproteins in
the human plasma and thus play a central role in atherogenesis. LDL-C has long
been touted as “bad cholesterol”, since elevated levels have been associated with
increased risk of coronary heart disease (CHD)16,17. Recently, the significance of
LDL-C on its own as a marker of CVD risk has come into speculation within certain
fields. Instead, LDL pattern type (A and B) has been receiving growing attention as a
more accurate marker of CVD risk.
Krause and Blanche122 where the first to divide the LDL gel electrophoresis
profile into two distinct phenotypes, which they referred to as patterns A and B.
Pattern A is distinguished by predominantly large-sized LDL, whereas pattern B is
composed of a greater proportion of small, dese LDL particles. Results from their
studies showed that ~25% of the sample population reported the pattern B
13

phenotype but that this was less frequent in women and younger subjects (<40 yrs).
Not surprisingly, pattern B was associated with moderate elevation in plasma TGs
and low levels of HDL-C54, a combination commonly termed the atherogenic
lipoprotein phenotype. Patients with combined hyperlipidemia exhibit this atherogenic
profile and are at an increased risk of CHD events regardless of their total LDL
circulating mass55.
In a similar fashion as mentioned previously, plasma TGs have been shown to
be the major determinant of the appearance of small, dense LDL particle’s,
regardless of the method of analysis54,56,57. Packard et al.55 observed that the pattern
B phenotype was infrequently seen in individuals with a plasma TG concentration
less than 115 mg/dL, while above this level, small, dense LDL increased in
propprotion to the plasma TG concentration.
The concern over small, dense LDL is that it has been shown to be more
readily oxidized, at least in vitro, than its larger pattern A counterparts. Additionally,
because of its reduced size it is likely to penetrate the aterial wall more easily, and
we have been able to demonstrate that LDL from pattern B subjects have an
enhanced affinity for arterial wall proteoglycan, thus prolonging its residence time in
the subendothelial space124. All of these features contribute to the enhanced
atherogenicity of this lipoprotein species.
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Effects of Low Carbohydrate High Fat Diets on Blood Lipids
One of the most consistent and predictable changes seen in those following a low
carbohydrate diet is a reduction in circulating triacylglycerols (TGs)9,123. The primary
mode of transport for TGs within the circulation is within very low-density lipoprotein
particles (VLDLs). It is theorized that increased production or synthesis of TGs within
the liver can increase the size and number of VLDLs synthesized and subsequently
released into the circulation by the liver10. Thus, by restricting carbohydrates in the
diet, lipogenesis within the liver, which occurs primarily from glucose derived sources
(denovolipogenesis or DNL) from the standard American diet, is greatly reduced or
entirely turned off. With DNL occurring at a much lower degree if it all, the liver has
less TGs to package and traffic and needs to synthesize less VLDL particles.
Serum cholesterol has long been of interest to both doctors and researchers.
Consistent among dietary intervention studies that measured TC, LDL-C and HDL-C
as outcome measures, is the large degree of individual variability10. This variability
has been shown in a range of studies looking at high and low fat intake 58 in the
presence of carbohydrates, high and low cholesterol in the presence of fat and
carbohydrates, and notably among low carbohydrate high fat intervention studies. It
is thought that some individuals are sensitive to changes in dietary cholesterol and fat
within the diet while others are insensitive. What’s more is that some believe varying
cholesterol responses may result largely from test error and that replication of the
same studies generates varying results59. The notion that cholesterol levels fluctuate
based on diet and activity is largely overlooked on a day-to-day basis. Large
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variability among cholesterol responses has been shown in those consuming various
diets.
Specifically, LCHFDs have been shown to reduce both fasting and
postabsorptive TGs in both over weight/obese individuals as well as healthy,
normolipidemic individuals10. This can largely be attributable to a reduction in
carbohydrates as was previously described. The cholesterol response to LCHFDs as
noted previously has been shown to be highly variable and is largely dependent on
cholesterol levels prior to the adherence of a LCHFD. On average, it appears both
TC and LDL-C increase following the consumption of a LCHFD in healthy
normolidemic individuals but among those who have higher levels of cholesterol the
response is different. HDL-C cholesterol has a more predictable response as it
increases in nearly all individuals10.

Effects of Low Carbohydrate High Fat Diets on Lipoproteins

Proposed Physiological Mechanism
A proposed theoretical mechanism for the effects of LCHF diets on circulating
lipoproteins has been previously described by Volek et al.10 (Figure 2).
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Figure 3: Paths up regulated during consumption of a LCHFD are represented by
solid lines and those down regulated by dashed lines

Fundamentally, adaptions that occur following a LCHFD result from a gluco-centric to
lipid-centric shift in metabolism. Continued ingestion of a LCHFD initially increases
circulating triacylglycerol (TAG)-rich chylomicrons, which are cleared rapidly by
lipoprotein lipase (LPL) bound to the luminal surface of capillary endothelial cells both
in skeletal muscle and adipose tissue56,104. Although not yet proven, it is likely
LCHFD increase muscle LPL as the main source of fuel switches from glucose to
fatty acids. Increased skeletal muscle LPL would thus facilitate TAG clearance.
Reduced carbohydrate consumption effectively reduces glucose and insulin levels,
indirectly decreasing adipocyte LPL and increasing hormone-sensitive lipase (HSL).
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This metabolic hormonal shift promotes TAG hydrolysis and increases fatty acid (FA)
rate and appearance throughout the body.
Increased skeletal muscle LPL is likely to result in LPL-mediated lipolysis of
newly formed chylomicrons, resulting in a release of FA that is either taken up by the
underlying tissue or escapes into the circulation. These circulating FAs are taken up
by the liver and preferentially diverted away from esterification to TAG and toward
mitochondrial oxidation to acetyl CoA. Accumulation for acetyl CoA exceeding the
capacity for mitochondrial oxidation results in the formation of ketones. Decreased
glucose availability for use by skeletal muscle shifts dependence towards fatty acids.
Thus, any increase in FA delivery to skeletal muscle is balanced (utilized) by an
increase in fat oxidation, as has been seen by postabsorptive respiratory exchange
ratios close to or below 0.7 (unpublished data).
Reduced hepatic production of TAG, which normally occurs from excess fatty
acids and glucose (Standard American diet), results in less VLDL synthesis and
secretion into the circulation. Furthermore, LPL-mediated lipolysis of VLDL results in
the transfer unesterified cholesterol, phospholipids (PL), and apolipoproteins to form
mature HDL-C. Remaining remnant particles are either taken up by the liver or
converted to LDL. Decreased circulating VLDL, particularly in the postprandial state,
results in less cholesterol ester transfer protein (CETP)-mediated neutral lipid
exchange with LDL-C. A reduction in hepatic lipase (HL) prevents larger LDL-C from
being delipidated to smaller, dense (atherogenic) LDL, producing a predominance of
larger LDL particles.
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Chapter 2

Introduction
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Low carbohydrate high fat diets (LCHFD) continue to show promise as a way
to improve the cardiometabolic profile, not only in at-risk populations, but also within
healthy individuals. Even so, long term safety and efficacy remain in question, as
longitudinal LCHF studies are limited5-7 and contradict current health
recommendations2,16. Variation in the cholesterol responses following adoption of a
LCHFD8-13,60,61 warrant concern as elevated cholesterol levels have been associated
with increased risk for cardiovascular diseases (CVD) and atherogenesis62.
Advances in our understanding that atherogenesis is lipoprotein mediated, not
cholesterol driven necessitate the need for more in depth comprehensive
investigations be conducted.
Cholesterol homeostasis (serum cholesterol levels) within the body reflects a
balance between endogenous cholesterol synthesis (hepatic and extra-hepatic) and
intestinal absorption (dietary and biliary cholesterol). Tight regulation of cholesterol
balance helps prevent a net accumulation of cholesterol both within the tissues and
circulation24,63 and disturbances in either input or output can increase atherogenic
progression39,42,64. Considering some individuals consuming a LCHF diet present with
increased cholesterol, whether or not this increase results from changes in
absorption or synthesis has yet to be confirmed. To date, no previous studies have
examined the response of a chronic low carbohydrate high fat diet on surrogate
markers of cholesterol balance in healthy, fit men.
Quantification of lipoprotein subfractions has become a well-recognized
means of assessing atherogenic risk65,66 and is arguably better67. Distribution of
lipoprotein subfractions towards a larger, more buoyant phenotype may help reduce
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atherogenic risk, where as increased remnant lipoproteins (VLDL) and small, dense
LDL particles may increase risk55. Smaller LDL particles are considered more
atherogenic because of their ability to more easily penetrate the arterial wall, and
their reduced binding affinity to the LDL receptor. This results in a prolonged
circulating half-life and thus increased susceptibility to oxidation68-71. In addition,
growing evidence suggests greater levels and size of triglyceride-rich lipoprotein
(TRL) particles, primarily VLDL remnants, are likely to contribute to atherogenic
risk72-74 through eventual conversion to small LDL particles68,75. Finally, it appears the
protective effects of HDL may be more largely attributable to large HDL particle
subfractions76.
Lipoprotein subfractions and surrogate markers of cholesterol balance provide
viable measures for evaluating the impact LCHFD have on overall long-term
cardiometabolic health. Such measures provide a far more detailed analysis of
metabolic risk than current clinical biomarkers (fasting total cholesterol, LDL
cholesterol, HDL cholesterol and triacylglycerides). Thus, the primary purpose of this
study was to compare the effects of a chronic (>6 months) LCHF diet to that of a high
carbohydrate (HC) diet on markers of lipoprotein metabolism and cholesterol
absorption and synthesis. We first hypothesized that increased consumption of
cholesterol among men following a chronic LCHF diet would not demonstrate a
significant shift in fractional cholesterol balance compared with those consuming a
chronic HC diet. Secondly, we hypothesized that a chronic LCHF diet would produce
a less atherogenic lipoprotein profile when compared to a HC diet. Despite increased
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circulating cholesterol levels among individuals consuming a chronic LCHF diet, we
propose that this cholesterol is carried in larger, less atherogenic lipoproteins.
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Chapter 3

Methods
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Experimental Approach
The following data is an extension of a larger cross-sectional investigation {Volek et
al 2015 pending} that reported on metabolic responses in two groups of elite ultramarathoners habitually consuming either a LC or HC diet. The purpose of the current
analysis was to more closely examine the effect of diet on markers of lipoprotein
metabolism and surrogate markers of cholesterol balance.

Participants
Twenty highly trained male ultra-endurance runners consuming a LC (n=10) or a HC
(n=10) diet 21-45 years of age were selected for participation. Athletes competed in
sanctioned running events ≥50 km and/or triathlons of at least half iron man distance
(113 km) and where in the top 10% of finalists. Athletes were carefully matched for
age, physical characteristics, primary competition distance, and competition times.
With one exception, all athletes lived in the United States and traveled via plane to
our laboratory for two days of testing. Interested athletes completed questionnaires to
assess their medical, diet, training, and running competition history. At least one
phone call was scheduled to review this information and determine eligibility and
availability. Diet information was entered into commercial nutrient analysis software
(Nutritionist ProTM, Axxya Systems, Stafford, TX). Subjects consuming a LC diet,
defined as <20%en from carbohydrate and >60%en from fat, consistently for at least
6 months were eligible for the LC group. Subjects consistently consuming >55%en
from carbohydrate were considered for the HC group. Athletes were excluded if they
did not consume the appropriate diet for the allotted amount of time or had any health
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issues, including, but not limited to diabetes, heart disease, kidney, liver, or other
metabolic or endocrine dysfunction, current injury, anti-inflammatory medication use,
anabolic drug use, or prone to excessive bleeding. Subjects were informed of the
purpose and possible risks of the investigation prior to signing an informed consent
document approved by the Institutional Review Board.

Measurements
Full methods have been described previously {Volek et al 2015 pending}. Briefly,
athletes arrived at the laboratory at 0600 after a 10 hr overnight fast and were asked
to restrict caffeine, over the counter medications, and alcohol. The night prior and
morning before testing, subjects were encouraged to liberally consume water to
ensure hydration. A small urine sample was provided to assess specific gravity
(Model A300CL, Spartan, Japan) as a measure of hydration (all subjects had a USG
>1.025). Body composition was determined by dual-energy X-ray absorptiometry
(DXA) (Prodigy, Lunar Corporation, Madison, WI). Height was measured to the
nearest 0.1 cm and total body weight was recorded to the nearest 0.1 kg on a digital
scale (OHAUS Corp., Fordham Park, NJ).

Blood Collection and Analysis
All blood samples were obtained with a 21G butterfly needle from an antecubital vein
of the subject. After resting quietly for 15 min in a supine position, blood was
collected into ethylenediaminetetraacetic acid (EDTA) and serum separator
vacutainer tubes (Vacuette, Greiner Bio-one North America, Inc., Monroe NC). EDTA
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tubes were immediately spun while serum tubes remained at room temperature for
15 min prior to centrifugation to allow clotting to occur. Whole blood was centrifuged
(1500 x g for 15 min at 4°C), promptly aliquoted into cryostorage tubes, snap frozen
with liquid nitrogen, and stored at -80°C for later analysis. One 10mL serum tube was
immediately sent on ice to a certified medical laboratory (Quest Diagnostics,
Wallingford, CT) for determination of glucose and other blood analytes using
automated enzymatic procedures (Olympus America Inc., Melville, NY).
Frozen samples were thawed only once before analysis of all variables. Baseline
EDTA plasma was analyzed for total cholesterol, HDL cholesterol, and triglycerides
using enzymatic methods on an automated analyzer (Cobas C 111, Roche
Diagnostics, Indianapolis, IN). Concentrations of total and LDL cholesterol were also
measured using standard enzymatic methods77,78.
Analysis of lipoprotein (high, low, and very low density lipoproteins [HDL, LDL,
and VLDL] particle size and number was conducted by Liposciences Inc. (Raleigh,
NC) using hydrogen nuclear magnetic resonance (H-NMR) on a 400 MHz NMR
analyzer (Bruker BioSpin Corp, Billerica, MA) as previously described by Jeyarajah
and colleagues79,80. Lipoprotein subclasses were grouped based on particle
diameters: large VLDL (>60 nm), medium VLDL (35–60 nm), small VLDL (27–35
nm), intermediate- density lipoproteins [IDL] (23–27 nm), large LDL (21.2–23 nm),
medium LDL (19.8–21.2 nm), small LDL (18–19.8 nm), large HDL (8.8–13 nm),
medium HDL (8.2–8.8 nm), and small HDL (7.3–8.2 nm). Lipoprotein insulin
resistance index (LP-IR) was calculated by Liposciences Inc. (Raleigh, NC) combing
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six lipoprotein measures (VLDL, LDL, and HDL size, large VLDL-P, small LDL-P, and
large HDL-P) into a single algorithm81.
Concentrations of noncholesterol sterol precursors (lathosterol, desmosterol,
cholestanol, sitosterol, and campesterol) were also quantified by Boston Heart
Diagnostics using a gas chromatography mass-spectrometry (GCMS) method similar
to that previously described82. To eliminate the effect of different cholesterol levels,
absolute values were standardized and expressed in terms of 10 2×mol/mmol of
cholesterol (ratios to cholesterol values).

Statistical Analysis
Means and standard deviation were calculated for all variables using conventional
methods. Differences between groups for demographic characteristics, diet,
lipoprotein subfractions, and surrogate markers of cholesterol balance were
assessed using independent samples t-tests. Normality testing was performed using
the Shapiro-Wilks test and non-normal data were analyzed with the Mann-Whitney U
test. Normal data with significant variance was analyzed using the Welches unequal
variance t-test. Relationships between variables were examined using Pearson’s
product-moment correlation coefficients. The level of significance was set at p ≤ 0.05.
All statistical analyses were preformed using Prism Graphpad (Software Version 6.0,
La Jolla, CA).
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Subject Characteristics and Diet
There were no significant differences between groups in physical characteristics or
aerobic capacity (Table 1). Two athletes in each group were triathletes and all others
competed in events largely ranging from 80 to 161 km (50 to 100 miles).
Primary differences between groups were among diet (Table 2). Total dietary caloric
intake and total macronutrient grams consumed (protein + fat + carbohydrates) did
not differ between groups (Table 2). Total grams of carbohydrate (p < 0.0001) and fat
(p < 0.0001) consumed were significantly different between groups for both the
habitual and pre-testing diets (Table 2, 3 and Figure 1). Individuals in the LC group
derived a majority of their energy from fat (70%), predominantly in the forms of
saturated and monounsaturated fatty acids. Only ~10% of energy intake was from
carbohydrate sources. Conversely, individuals in the HC group consumed over half
their energy in the form of carbohydrates (57%). Protein was not significantly
different between groups. Notably, dietary cholesterol intake was significantly greater
(p < 0.003) in the LC group (844 mg/day) compared with the HC group (291 mg/day)
(Table 2). The average duration on a LC diet ranged from 9 to 36 months.

Plasma Lipids
Men consuming a LCHF diet had significantly greater (p < 0.0001) serum total
cholesterol (64.6%), LDL-C (p < 0.0001) (83.1%), and HDL-C (p < 0.0007) (52.9%)
compared to the HC group (Table 4, Figure 2). This did not however adversely affect
the HDL-C to triglyceride ratio. Serum triglycerides were not different between
groups, although LCHF men had a significantly (p < 0.0113) lower TG/HDL ratio.
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Fractional Cholesterol Balance and Noncholesterol Sterols
No significant differences existed between groups following the calculation of
fractional cholesterol balance [Fractional Cholesterol Balance = (lathosterol × 0.8 +
desmosterol × 0.2)/(beta-sitosterol × 0.5 + campesterol × 0.5)]. Absolute and
normalized sterol levels are presented in (Table 8). Non-cholesterol sterols are
transported in plasma by lipoproteins and to correct for variations in lipoprotein levels,
sterol concentrations are frequently expressed relative to the concentration of total
cholesterol (μmol/mmol of cholesterol). Absolute levels of each measured sterol were
greater in the LCHFD group with desmosterol (p < 0.0003) and cholestanol (p <
0.0087) being significant. When normalized to cholesterol, all sterol values apart from
desmosterol where greater in the HCD group. Normalized values of lathosterol (p <
0.0158), desmosterol (p < 0.0455), cholestanol (p < 0.0026), and campesterol (p <
0.0185) were significantly different between groups.

Noncholesterol Sterols Related to Serum Cholesterol
The serum concentrations of all noncholesterol sterols were significantly correlated
with HDL cholesterol (Table 9). In addition, all sterols but campesterol where
significantly correlated with total and LDL cholesterol. When values were normalized
to cholesterol, noncholesterol sterol levels were no longer correlated with total
cholesterol and only desmosterol and campesterol remained significantly correlated
with LDL cholesterol. Cholestanol was the only sterol to remain correlated with HDL
cholesterol.
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VLDL, LDL, and HDL Particle Size and Quantity and LP-IR
VLDL particle size, but not total particle number, was significantly lower (p < 0.0022)
(-14.3%) in men who consumed a LCHF diet (Table 5). Of the varying particle sizes,
only large VLDL particles were significantly (p < 0.0062) lower (-126.8%) in the LCHF
group compared to the HC. Both groups presented with large pattern A particles
(Table 6). Those following a LCHF diet had significantly larger (p < 0.0102) LDL
particles. Total LDL particle number was significantly higher (p < 0.0021) by 52.7%
in the LCHF group; however, this significant difference was caused by a 124.8%
increase (p < 0.0001) in the large and a 140.2% increase (p < 0.0021) in the
intermediate particles. Although not statistically significant (p < 0.1013) due to large
variation within the HC group and outliers in the LCHF group, median small particle
size (most atherogenic), was 126% greater in the HC group. Upon removal of two
LCHF outliers, however, the difference between groups becomes significant (p <
0.083) and the percent change more than doubles (264.8%). Men consuming a
LCHF diet had HDL particles significantly (p < 0.0053) larger (7.3%) than those
consuming a HC diet (Table 7). Total HDL particles were not different between
groups; however, men in the LCHF group had significantly greater (p < 0.0013) larger
particles (82.6%), and significantly (p < 0.0038) less (-56%) medium particles
compared to the HC group. Small HDL particles were not different between groups.
The lipoprotein insulin resistance index (LP-IR) was significantly lower in the LCHF
group by 360% (p < 0.0001) revealing a significantly reduced predictive risk for
insulin resistance (Table 4, Figure 3).
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In the present study, we sought to compare the lipoprotein and cholesterol
responses in healthy, active, normal-weight men who were chronically adapted to
either a low carbohydrate high fat diet (LCHFD) or a high carbohydrate diet (HCD).
LCHFDs continue to remain controversial in regards to their impact on health and
long-term safety83, and while few long-term studies (> 6 months) have sought to
validate LCHFD in this realm, only cholesterol mass responses in obese participants
have been measured4-7. Thus to date, this is the first study to measure surrogate
markers of cholesterol synthesis and absorption as well as the lipoprotein profile in
healthy, active, normal-weight men adapted to a LCHFD (> 6 months).
LCHFDs have received criticism for their potential to increase circulating
serum cholesterol mass. Previously conducted short-term LCHFD studies in healthy,
normolipidemic subjects corroborate these findings8-13, however, frequently
disregarded is the notion that individual cholesterol responses following a LCHFD
can be highly variable13 and are elevated as a result of significant increases in HDLC. Despite significant increases in dietary and circulating cholesterol, we proposed
men following a long-term (> 6 month) LCHFD would not demonstrate altered
fractional cholesterol balance and would exhibit favorable changes in circulating
lipoproteins subfractions.

Plasma Lipids
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Mean dietary cholesterol intake among men following a LCHFD was 190%
greater (553 mg/d), or more than triple those consuming a HCD. Based on previously
conducted LCHF studies in healthy normolipidemic men8-13, elevated cholesterol in
our LCHF group was not unexpected; TC, LDL-C, and HDL-C were significantly
higher by 64.6%, 83.1%, and 52.9% respectively. Correspondingly, we found dietary
cholesterol intake demonstrated significant correlations with cholesterol measures
(TC: r = 0.75, p < 0.0001; LDL-C: r = 0.71, p < 0.0005; HDL-C: r = 0.54, p < 0.0135).
Elevated cholesterol in the LCHF group suggests a potential hyper responsiveness to
dietary cholesterol, however this was not possible to determine given the crosssectional nature of the study. Regardless, hyper-absorption in response to increased
dietary cholesterol consumption is unlikely to explain such a dramatic elevation in
cholesterol levels in men as fit as ours84.
Consistent with variable cholesterol responses, men in the LCHFD group
displayed a greater range of TC values (LCHF = 162, HC = 65) than men in the HC
group. Cholesterol feeding has previously been shown to produce large
interindividual variability in circulating cholesterol19. Furthermore, leanness of the
subjects may have contributed to a more dramatic response 18,85. Such disparity in the
responsiveness of blood cholesterol following the adoption of a LCHFD is thought to
occur largely from individual variations in hormonal factors, obesity, and genetic
predisposition19, although this has yet to be fully determined. Both groups had
extremely favorable HDL-C levels (> 40mg/dL), a trait likened to a the elite fitness
level of our subjects86.
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High HDL-C levels among athletes is not uncommon87. It has been well
established that endurance training increases HDL-C cholesterol88,89 and promotes
enhanced cholesterol efflux90. Various physiological mechanisms have been
attributed to this adaptation including increased LPL activity91, decreased cholesterol
ester transfer protein (CETP)92, and increased expression of ABCA1 transporters
necessary for HDL genesis93. Even more notable were the significantly greater HDLC levels among men in the LCHF group. To our knowledge, further increases in HDLC beyond those seen with exercise can only be attributed to differences in diet as TG
levels were not significantly different between groups. Short term LCHFDs
consistently show positive changes in circulating HDL-C levels among normal
weight11,60 and overweight individuals94-96. Studies evaluating the long-term (> 6 mo)
HDL-C response in healthy men has yet to be conducted, however those carried out
in obese patients have show increases in HDL-C5-7. Considering this fact, it is not
unreasonable to expect significantly elevated HDL-C following chronic LCHFD in
healthy fit men.
Surrogate Markers of Cholesterol Synthesis and Absorption
Plasma non-cholesterol sterols can be measured to assess cholesterol
homeostasis and correlate strongly with absolute cholesterol synthesis and
absorption44,97,98. With varied cholesterol responses previously reported in men
consuming LCHFDs8-13, we sought to assess whether a chronic ( > 6 months) freeliving LCHFD shifts cholesterol homeostasis in favor of synthesis or absorption. The
ratio of cholesterol synthesis markers (lathosterol and desmosterol) to absorption
markers (beta-sitosterol and campesterol) can be used to calculate fractional
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cholesterol balance. A reduced ratio (< 0.5) is indicative of greater serum phytosterol
concentrations and increased cholesterol absorption at the gut lumen where as
raised fractional values ( > 1.1) are representative of elevated cholesterol precursors
and imply increased synthesis of cholesterol. To date, no previous long-term LCHFD
studies have utilized these surrogate markers to assess cholesterol balance in
healthy, fit, individuals.
Quite remarkably, calculated mean fractional cholesterol balance was similar
between groups (LCHF = 0.66, HC = 0.60) and was not indicative of increased
absorption or synthesis. Given that men in the LCHFD group consumed significantly
greater levels of dietary cholesterol and maintained significantly greater levels of
circulating cholesterol, this finding was noteworthy. Extrapolation of these findings
may suggest men who follow a chronic LCHFD expand their endogenous cholesterol
pool before establishing a new circulating homeostatic level18,99. Similar to cholesterol
levels, we found surrogate markers in both groups to be greatly variable, in line with
other findings32, and further substantiating an individualized, likely genetic, response
to diet.
Noncholesterol sterols are novel biomarkers not yet endorsed by international
guidelines, but can be useful in determining clinical approaches for elevated
cholesterol (hypercholesterolemia)29. Although men following a LCHFD were
hypercholesterolemic (TC > 200mg/dL), all normalized sterol levels except
desmosterol were greater in the HC group. Considering current recommended
ranges for normalized sterol levels have been established using data from patients
consuming a traditional American diet, normalizing noncholesterol sterols many not
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be appropriate for assessment of over absorption and synthesis in LCHF adapted
individuals. Greater absolute sterol values in the LCHF group were not surprising
given the elevated cholesterol levels in those men. Significantly greater absolute
desmosterol levels in the LCHF men would seem to imply greater production of
cholesterol, however, the pathway through which desmosterol forms cholesterol is
thought to contribute far less to overall synthesis than the lathosterol, which was not
significantly different between groups. Apart from campesterol, absolute values of
noncholesterol sterols showed significant positive corrections with total, LDL, and
HDL cholesterol supporting the relationship between elevated sterol biomarkers and
circulating cholesterol levels. We are the first to measure noncholesterol sterols in
healthy, fit men, making it difficult to fully elucidate our findings. The effect exercise
training has on surrogate cholesterol markers remains to be seen and further
research is necessary to understand how noncholesterol sterols levels respond to
long term LCHFDs.

Lipoprotein Particle Distribution, Size, and LP-IR
NMR analysis revealed favorable, pattern A, lipoprotein profiles in both
groups. Considering the elite fitness level among men recruited for this study, we
acknowledge that adaptation to endurance exercise influences lipoprotein particle
distribution independent of diet86,88. Nonetheless, we found a LCHFD resulted in an
even more favorable lipoprotein profile (less atherogenic) compared to consuming a
HCD. Though pattern type (A or B) is influenced by genetic inheritance 54, dietary
change can also alter particle distribution, particularly atherogenic LDL subclasses56.
37

In support of previous literature11,14,100, reduced carbohydrate consumption
among men following a LCHFD (< 100 g/day), in combination with less circulating
TGs (-10.4%) and VLDLs (-27.9%), is likely the primary contributing factor towards an
atheroprotective shift in lipoprotein metabolism (less atherogenic LDL particles [LDLP] and greater atheroprotective HDL particles [HDL-P]). Still, cholesterol feeding with
eggs has been shown to favorably alter LDL subclasses84. Dietary carbohydrate
reduction has consistently been shown to result in a significant decrease in both
fasting and postprandial TGs1,11,14,100. Due to the natural metabolism of TG rich
VLDLs to LDLs, a reduction in TGs results in less VLDL synthesis by the liver and
therefore a direct reduction in circulating LDL particles10. In addition, reduced
circulating TGs decrease cholesterol-TG transfer between TG rich-VLDLs and LDL
via CETP, allowing for HDL and LDL to carry a greater capacity of cholesterol,
resulting in larger, more buoyant lipoproteins101.
Differences in TGs and VLDL subfractions among groups is likely attributable to a
combination of reduced carbohydrate consumption, reduced VLDL production rate,
shown to increase on a high carbohydrate diet102, and an increase in TG removal
given high-fat diets ( > 45% total energy) promote increased postheparin plasma and
skeletal muscle LPL activity in humans56,103,104. Reduced TGs are likely responsible
for a significant 14.3% reduction in mean VLDL particle (VLDL-P) size, reduced total
number, and decreased size of VLDL-P subfractions. Significant positive correlations
between circulating TGs and VLDL particle count and subfractional size support this
assessment (Total VLDL-P: r = 0.94, p < 0.0001; Large VLDL-P: r = 0.66, p < 0.0016;
Medium VLDL-P: r = 0.88, p < 0.001; Small VLDL-P: r = 0.64, p < 0.0026). Although
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LCHF adapted men had less total, large, medium, and small VLDL-P compared to
men in the HCD group, only large VLDL-P were found to be significantly lower as a
result of wide particle variation among participants.
Reduced VLDL-P size among men adapted to LCHFDs affected LDL particle
size. Smaller denser LDL particles evolve from elevated levels of TGs and thus larger
VLDL particles22,68,105,106, primarily as a result of hepatic lipase101. This was evident in
the men adapted to a LCHFD as supported by the strong negative relationship
between the two measures (r = -0.70, p < 0.006). Convincingly, mean LDL particle
size was significantly greater in the LCHF group compared to the HCD group. Total
LDL particle count was 52.7% greater among men consuming a LCHFD, however,
the distribution of LDL particles was dominated by large and intermediate particles
(88.2% of total particles) while in the HC group, large and intermediate particles
made up 59.3% of total LDL particles.
Of considerable importance are the findings related to small LDL-P, those
attributed with an increased risk of CVD54,57,107. Two men within the LCHF group
prevented small LDL particles from being statistically significant between groups.
Regardless, small LDL particles comprised 40.7% of total particles in men who
consumed a HCD compared to only 11.8% in men on a LCHFD. As a whole, HC men
had 126% more small LDL particles than those in the LCHF group. Considering LDLC levels in the LCHF group were nearly double those in the HC groups (161.3 vs
88.1 mg/dL), these findings suggest elevated LDL-C in men consuming a chronic
LCHFD does not contribute to the development of atherogenic small LDL-P and that
elevated LDL-C may not be a good predictor of atherogenesis in those who follow a
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LCHFD. These findings support previous LCHF studies which demonstrate restricting
dietary carbohydrate increases mean LDL particle size, reduces small LDL-P, and
subsequently shifts particle pattern11,14,60,94,108-112.
Carbohydrate restriction, reduced TGs, and increased dietary cholesterol can
similarly be attributed to the positive shift in HDL lipoproteins. Mean HDL size was
significantly larger in the LCHFD group, suggesting a reduced uptake of HDL
particles by the liver and thus increased circulating HDL-C concentrations111,112.
Although not statistically different, total HDL-P were greater in the LCHF group. Large
atheroprotective HDL particles76,113 were significantly greater in the LCHF group
accounting for 39.6% of total particles, in contrast to 23.9% in men consuming a
HCD. Although not measured in the current study, cholesterol ester transferase likely
plays a role increasing large HDL particles in the LCHF group114. Interestingly, men
on a HCD had a 56% greater number of medium HDL particles compared to the
LCHF group. Because men following a LCHFD had reduced circulating TGs, it is
probable that neutral lipid exchange between VLDL and HDL lipoproteins was
reduced, resulting in the formation of fewer TG-rich HDL particles. If HDL particles
contained less TGs, it would reduce their susceptibility to remodeling by hepatic
lipase, yielding fewer small HDL particles14.
The lipoprotein insulin resistance index (LP-IR) is an effective tool to
summarize the NMR results. The LP-IR index is an algorithmic system which gives
numeric weight to six parameters of the NMR lipoprotein profile test associated with
insulin resistance115-117 (VLDL, LDL, and HDL size, large VLDL-P, small LDL-P, and
large HDL-P). The final LP-IR score is calculated by summing the six NMR parameter
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scores81. Shalaurova et al.81 recently demonstrated the value of the index in
predicting insulin resistance. Although both groups in the present study were
comprised of healthy fit males who’s mean LP-IR scores fell just at or below the 25th
percentile (< 25), those following a LCHFD showed an astoundingly lower (-360%)
LP-IR score. Knowing that insulin resistance precedes the development of obesity,
metabolic syndrome, and type 2 diabetes mellitus, such a significantly lower LP-IR
score in men consuming a LCHFD, even among healthy fit individuals, provides
further evidence for the therapeutic potential of LCHFDs in treating these metabolic
abnormalities.
Despite significantly greater consumption of dietary cholesterol by men
consuming a chronic LCHFD, surrogate markers of cholesterol synthesis and
absorption did not reveal a direct cause (increased synthesis or absorption) for
elevated serum cholesterol (TC, LDL-C, and HDL-C) within the LCHF group.
Although speculative, individuals who adopt a LCHFD may experience an expansion
of their endogenous cholesterol pool during the adaptation phase of the diet, after
which they maintain greater circulating cholesterol levels but no increased risk for
CVD. Increased cholesterol consumption, elevated cholesterol levels, and low rates
of heart disease in indigenous Inuit populations suggest this may be true 118-121. In
further support of this theory, we found that regardless of an increase in total and
LDL cholesterol within the LCHFD group, these men had more favorable lipoprotein
profiles in regards to CVD risk than those consuming a HCD, notably less small LDL
particles. Current evidence suggests CVD is lipoprotein-mediated, leaving
measurements of circulating cholesterol nearly obsolete in their efficacy for predicting
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heart disease. Additional research is necessary to fully determine if elevated LDL
cholesterol in LCHF individuals presents an increased risk for CVD.
Limitations of this study include small sample size, cross-sectional design,
surrogate measures of cholesterol balance rather than absolute cholesterol turnover,
and lack of measured variables such as enzymes important in lipoprotein metabolism
and markers of LDL oxidation. These data should be regarded as pilot data requiring
future, more in-depth studies be conducted to fully determine the meaning of these
data. Increased cholesterol did not occur as a result of over absorption or synthesis
as measured by surrogate markers and suggests the body may maintain a new
homeostatic set point upon adaptation to a LCHFD. Our findings support the notion
that long-term LCHFD can increase circulating cholesterol mass but in so doing, shift
lipoprotein size and particle distribution towards a more favorable less atherogenic
profile.
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Tables & Figures
Table 1. Baseline Subject Demographics1

Age (yr)
Height (cm)
Body Mass (kg)
Body Fat (%)2
Lean Mass (kg)2
Fat Mass (g)
VO2max (mL/kgmin)
1Values

High Carb

Low Carb

32.9 ± 6.0
173.9 ± 5.3
66.5 ± 6.8
9.6 ± 4.3
57.3 ± 5.0
6.5 ± 3.6

34.1 ± 7.1
175.7 ± 6.5
68.8 ± 8.2
7.8 ± 2.4
60.9 ± 7.1
5.46 ± 1.8

64.6 ± 6.1

64.6 ± 4.3

are mean ± SD (n=10).
by dual-energy X-ray absorptiometry.

2Determined

Table 2. Daily macronutrient breakdown for habitual diet1
Habitual Diet2

High Carb

Low Carb

Energy (kcal/day)
Protein (g/day)
Protein (%en)
Protein (g/kg)
Carbohydrates (g/day)
Carbohydrates (%en)
Fat (g/day)
Fat (%en)
Saturated fat (g/day)
Monounsaturated fat (g/day)
Polyunsaturated fat (g/day)
Alcohol (%en)
Cholesterol (mg/day)
Fiber (g/day)

3044 ± 604
117 ± 39
14.9 ± 3.9
1.7 ± 0.4
442 ± 116
56.5 ± 10.2
94 ± 33
26.7 ± 7.5
22 ± 10
32 ± 16
17 ± 9
1.8 ± 2.7
291 ± 256
48 ± 15

2884 ± 814
139 ± 32
19.4 ± 2.4
2.1 ± 0.6
82 ± 62****
10.4 ± 4.9****
226 ± 66****
69.5 ± 6.0****
86 ± 22****
82 ± 42***
28 ± 17
0.7 ± 1.4
844 ± 351**
23 ± 17**

1Values

are mean ± SD (n=10).
24-Hr food record including one weekend day.
Asterisks indicate significant difference between groups:
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
23-Day
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Table 3. Daily macronutrient breakdown for pre-testing diet1
Pre-testing Diet2

High Carb

Low Carb

Energy (kcal/day)
Protein (g/day)
Protein (%en)
Protein (g/kg)
Carbohydrates (g/day)
Carbohydrates (%en)
Fat (g/day)
Fat (%en)
Saturated fat (g/day)
Monounsaturated fat (g/day)
Polyunsaturated fat (g/day)
Alcohol (%en)
Cholesterol (mg/day)
Fiber (g/day)

2856 ± 846
118 ± 41
16.4 ± 3.5
1.7 ± 0.4
371 ± 107
50.9 ± 5.0
95 ± 26
29.5 ± 2.8
25 ± 9
29 ± 17
16 ± 3
3.2 ± 4.2
302 ± 364
37 ± 13

2572 ± 597
148 ± 34
23.2 ± 5.7
2.2 ± 0.7
64 ± 27****
10.4 ± 5.4****
195 ± 65**
66.0 ± 8.8****
79 ± 37**
69 ± 29*
19 ± 7
0.3 ± 0.7*
883 ± 320**
20 ± 12*

1Values

are mean ± SD (n=10).
24-Hr food record prior to test day.
Asterisks indicate significant difference between groups:
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
22-Day
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Dietary Macronutrient Distrubution
Habitual 3-Day
High CHO
Carbohydrates
Fat
Protein

14.9%
26.7%

Low CHO
10.4%
31.1%

Carbohydrates
Fat
Protein

56.5%
69.5%

Pre-test Day
Low CHO

High CHO
Carbohydrates
Fat
Protein

16.4%
29.5%

10.4%
23.2%

50.9%
66.0%

Figure 1: No statistical differences between Habitual Diet and Pre-test Day
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Carbohydrates
Fat
Protein

Table 4. Serum Cholesterol and Lipids 1
Variable

High Carb

Low Carb

Total Cholesterol (mg/dL)
LDL Cholesterol (mg/dL)
HDL Cholesterol (mg/dL)
Total Cholesterol/HDL Cholesterol
Triglycerides (mg/dL)
Triglycerides/HDL Cholesterol
Lipoprotein Insulin Resistance Index2

168.7 ± 24.4
88.1 ± 13.68
63.9 ± 17.99
2.74 ± 0.47
70.0 ± 25.09
1.15 ± 0.49
26.7 ± 10.47

277.7 ± 50.58****
161.3 ± 37.38****
102.3 ± 26.21**
2.81 ± 0.53
63.4 ± 17.26
0.67 ± 0.23*
5.8 ± 5.75***

1Values

are mean ± SD (n=10).
algorithm of six lipoprotein measures.
To convert to SI units, multiply total cholesterol, LDL-C, HDL-C (mg/dL) × 0.0256 = mmol/L;
multiply triglycerides (mg/dL) × 0.0113 = mmol/L.
Asterisks indicate significant difference between groups:
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
2Combined
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Total Cholesterol (mg/dL)

****

400
320
240

277.7 ± 50.58

160
80

168.7 ± 24.4

0

***

LDL-C (mg/dL)

250
200

High Carb

150

Low Carb

100
50

161.3 ± 37.38
88.1 ± 13.7

0

**

HDL-C (mg/dL)

150
120
90
60
30

102.3 ± 26.2
63.9 ± 18.0

0
Figure 2: Total, LDL, and HDL cholesterol group spread values.
Values are mean ± SD (n=10).
Asterisks indicate significant difference between groups:
**P < 0.01; ***P < 0.001; ****P < 0.000
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Table 5. VLDL size and concentration of total VLDL particles and VLDL subfractions 1
Variable
VLDL Particle Size (nm)
Total VLDL Particles (nmol/L)
Large VLDL Particles (nmol/L)
Medium VLDL Particles (nmol/L)
Small VLDL Particles (nmol/L)

High Carb

Low Carb

43.65 ± 1.72
48.10 ± 25.47
1.27 ± 0.70
13.55 ± 15.36
33.26 ± 14.29

38.2 ± 4.09**
37.61 ± 5.90
0.56 ± 0.09*
4.12 ± 3.70
32.94 ± 18.41

1Values

are mean ± SD (n=10).
Asterisks indicate significant difference between groups:
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001

Table 6. LDL size and concentration of total LDL particles and LDL subfractions 1
Variable
LDL Particle Size (nm)
Total LDL Particles (nmol/L)
Large LDL Particles (nmol/L)
Intermediate LDL Particles (nmol/L)
Small LDL Particles (nmol/L)

High Carb

Low Carb

20.99 ± 0.35
892.8 ± 195.8
456.4 ± 101.0
73.4 ± 76.92
363.0 ± 245.2

21.47 ± 0.34**
1363 ± 343.1**
1026 ± 258.9****
176.3 ± 63.87**
160.6 ± 134.8

1Values

are mean ± SD (n=10).
Asterisks indicate significant difference between groups:
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001

Table 7. HDL size and concentration of total HDL particles and HDL subfractions1
Variable
HDL Size (nm)
Total HDL Particles (nmol/L)
Large HDL Particles (nmol/L)
Medium HDL Particles (nmol/L)
Small HDL Particles (nmol/L)
1Values

High Carb

Low Carb

9.51 ± 0.47
33.96 ± 5.35
8.1 ± 3.41
12.9 ± 3.06
12.96 ± 5.54

10.2 ± 0.47**
37.38 ± 4.43
14.79 ± 4.41**
8.27 ± 3.18**
14.31 ± 5.19

are mean ± SD (n=10).
Asterisks indicate significant difference between groups:
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
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High Carb
Low Carb

**

45
40

43.6 ± 1.7

35

38.2 ± 4.1

30

4

Large VLDL-P (nmol/L)

VLDL Particle Size(nm)

50

21.5
21.0

21.5 ± 0.3

Small LDL-P (nmol/L)

LDL Particle Size (nm)

**

1.3 ± 0.6
0.6 ± 0.3

800
600
400
200
0

20.1 ± 0.4

363.0 ± 245.2

**

11
10

9.5 ± 0.5

10.2 ± 0.5

8

20
15
10

14.8 ± 4.4

5
0

Figure 3: Lipoprotein Insulin Resistance Index Measures.
Values are mean ± SD (n=10).
Asterisks indicate significant difference between groups:
**P < 0.01
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160.6 ± 134.8

**

25

Large HDL-P (nmol/L)

12

HDL Particle Size (nm)

**

1

1000

22.0

9

2

0

22.5

20.5

3

8.1 ± 3.4

Table 8. Fractional cholesterol balance and non-cholesterol sterols 1

Fractional Cholesterol Balance2

High Carb

Low Carb

0.60 ± 0.16

0.66 ± 0.22

Absolute (mg/L)
Desmosterol
Lathosterol

1.42 ± 0.24
1.84 ± 0.55

2.82 ± 0.80***
2.23 ± 0.61

Campesterol
Sitosterol

3.5 ± 1.46
3.07 ± 1.03

3.86 ± 1.37
4.34 ± 1.75

Cholestanol

2.23 ± 0.44

2.8 ± 0.43**

Normalized (102 x μmol/mmol of TC)
Desmosterol
Lathosterol

84.8 ± 11.55
109.4 ± 30.67

101.9 ± 22.35*
79.6 ± 14.41*

Campesterol
Sitosterol

195.0 ± 59.04
167.7 ± 44.65

134.7 ± 43.98*
145.8 ± 55.03

Cholestanol

132.3 ± 24.44

101.5 ± 13.4**

1Values

are mean ± SD (n=10).
with normalized values
Asterisks indicate significant difference between groups:
*P < 0.05; **P < 0.01; ***P < 0.001
2Calculated
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Table 9. Correlations of serum noncholesterol sterols with serum total and
lipoprotein cholesterol levels among healthy, fit men (n=20)
Serum Cholesterol (mg/dL)
Sterols
Total Cholesterol
LDL Cholesterol
HDL Cholesterol
Absolute (mg/L)
Desmosterol
Lathosterol

0.8851****
0.6231**

0.9169****
0.5900**

0.5972**
0.5413*

Campesterol
Sitosterol

0.4327
0.6179**

0.2528
0.5042*

0.5321*
0.6268**

Cholestanol

0.7141***

0.6106**

0.6162**

Normalized (102 x μmol/mmol of TC)
Desmosterol
Lathosterol

0.3963
-0.4269

0.5262*
-0.3877

0.07971
-0.3359

Campesterol
Sitosterol

-0.3318
-0.1371

-0.4561*
-0.2114

-0.1279
0.005034

Cholestanol

-0.6654

-0.0348

-0.5312*

Both groups (n=20), Low Carb (n=10), High Carb (n=10)
Asterisks indicate significant difference between groups:
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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